Why Tempus AI Stock Rose Today
Key Points
Healthcare leaders are partnering with Tempus AI to bolster their development pipelines.
Tempus' sales are expanding at a rapid pace.
- 10 stocks we like better than Tempus AI ›
Shares of Tempus AI (NASDAQ: TEM) popped on Monday after the health technology specialist issued an upbeat sales forecast.
By the close of trading, Tempus AI's stock price was up more than 4% after rising as much as 15% earlier in the day.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
This AI business is booming
Tempus expects revenue to grow 83% year over year to $367 million in the fourth quarter, fueled by a 121% surge in diagnostics sales, to $266 million, and a 25% jump in data and applications revenue, to $100 million.
For the full year, the artificial intelligence (AI)-focused healthcare company forecast sales growth of 83% to $1.27 billion. Excluding its acquisition of Ambry Genetics in early 2025, Tempus projects its organic sales to grow by 30%.
"We enter 2026 in an exceptionally strong position with both of our main businesses accelerating in growth and delivering the financial leverage inherent in our platform," CEO Eric Lefkofsky said in a press release.
Tempus AI is supporting the pharma industry's drug discovery efforts
Tempus also announced record total contract value of more than $1.1 billion as of Dec. 31. The precision medicine enabler signed data deals with over 70 clients in 2025. Pharmaceutical giants like Pfizer, Novartis, and Eli Lilly are integrating Tempus' datasets into their drug development programs.
Better still, Tempus' existing customers are spending more on its data offerings, as evidenced by its impressive net revenue retention of roughly 126% in 2025.
Investors will have an opportunity to review Tempus AI's finalized results when it reports earnings in February.
Should you buy stock in Tempus AI right now?
Before you buy stock in Tempus AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $482,451!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,229!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of January 12, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
